Incyte | INCY - Gewinn Vor Steuern

Aktienkurs
97.80
Täglich Wechseln
2.08 2.17%
Monatlich
8.27%
Jährlich
61.84%
Q2 Prognose
92.62




Gewinn Vor Steuern Veränderung Datum
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Agenus USD -10.61M 263.52M 2025-12
Agios Pharmaceuticals USD -109.06M 5.62M 2025-12
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Amgen USD 3.92B 2.35B 2025-09
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Biogen USD 557.3M 186.7M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Eli Lilly USD 7.23B 456M 2025-09
Exelixis USD 252.69M 275K 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
Incyte USD 389.94M 92.37M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
MacroGenics USD -14.93M 31.75M 2025-12
Merck USD 6.74B 22M 2025-09
Moderna USD -187M 631M 2025-09
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Novartis USD 4.64B 445M 2025-12
Novartis USD 5.17B 637M 2025-09
Pfizer USD 3.33B 290M 2025-09
PTC Therapeutics USD -139.08M 116.01M 2025-12
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09